Paradigm Biocapital Advisors LP: EDGEWISE THERAPEUTICS, INC. (EWTX): Quarterly 13F Position History
As of Q1 2026, Paradigm Biocapital Advisors LP reported 7,365,038 shares of EDGEWISE THERAPEUTICS, INC. (EWTX), worth $232.0M and representing 4.7% of its 13F equity book. Quarter-over-quarter share count change: + 823,828 (+12.6%) . The position first appeared in Q1 2024 and has been disclosed across 9 13F-HR filings in Pactolio's tracked window.
- 7,365,038Shares Held (Latest Filing)
- $232.0MReported Market Value (Latest Filing)
- 4.7%Portfolio Weight (% of 13F Equity Book)
- +823,828Quarter-over-Quarter Share Change
- +$69.7MQuarter-over-Quarter Value Change
- 7,365,038Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 9 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 7,365,038 | +823,828 | +12.6% | $232.0M | 4.7% | $31.5 |
| Q4 2025 | 6,541,210 | +371,079 | +6.0% | $162.3M | 4.3% | $24.8 |
| Q3 2025 | 6,170,131 | +27,787 | +0.5% | $100.1M | 3.0% | $16.2 |
| Q2 2025 | 6,142,344 | +1,747,788 | +39.8% | $80.5M | 3.4% | $13.1 |
| Q1 2025 | 4,394,556 | 99,373 | -2.2% | $96.7M | 4.5% | $22.0 |
| Q4 2024 | 4,493,929 | +1,704,757 | +61.1% | $120.0M | 4.2% | $26.7 |
| Q3 2024 | 2,789,172 | +463,723 | +19.9% | $74.4M | 2.6% | $26.7 |
| Q2 2024 | 2,325,449 | 120,924 | -4.9% | $41.9M | 1.6% | $18.0 |
| Q1 2024 | 2,446,373 | — | — | $44.6M | 1.6% | $18.2 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Paradigm Biocapital Advisors LP first disclose a EWTX position in 13F-HR filings?
Paradigm Biocapital Advisors LP first reported EDGEWISE THERAPEUTICS, INC. (EWTX) on its 13F-HR filing for the period ending 2024-03-31 (Q1 2024). The position has appeared on 9 reported quarters within Pactolio's tracked window.
What was Paradigm Biocapital Advisors LP's most recent quarter-over-quarter share-count change in EWTX?
Between Q4 2025 and Q1 2026, Paradigm Biocapital Advisors LP added 823,828 shares of EWTX (+12.6%), bringing the total reported position to 7,365,038 shares at a market value of $232.0M.
Does the implied price-per-share represent Paradigm Biocapital Advisors LP's cost basis in EWTX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.